


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on Dec. 8, 2000

Dara M. Kendall 43,709
Name of Attorney Registration No.
Dara M. Kendall
Signature of Attorney



Case 7730R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :

RABE ET AL. :

Serial No.: 09/629,734 :

Group Art Unit: 3751

Filed: July 31, 2000 :

Examiner:

For: ELECTROSTATICALLY-SPRAYABLE TOPICAL COMPOSITIONS
HAVING INSULATING EXTERNAL PHASE AND CONDUCTIVE
INTERNAL PHASE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
DEC 19 2000
TC 3700 MAIL ROOM

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO-1449 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

**THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO
(2) OR (3) MARKED WITH AN (X) ABOVE.**



(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed. It is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311 as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s ____, were submitted and considered in parent application U.S. Patent Application Serial No. ____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s ____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s ____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c); a concise explanation of the relevance of each cited reference that is not in the English language is on the attached page, except where a full English language translation is provided.

☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page, the copies of which are attached.

☐ Additional information is attached.

Respectfully submitted,

By *Dara M. Kendall*
 Dara M. Kendall
 Attorney for Applicants
 Registration No. 43,709
 (513) 627-0081

RECEIVED
 DEC 19 2000
 TC 3700 MAIL ROOM

Rae. J., 2000
 Miami Valley Laboratories
 P. O. Box 538707
 Cincinnati, OH 45253-8707

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
7729R	09/628,631	Yen et al.	7/31/2000
7731R	09/629,765	Rabe et al.	7/31/2000
7732R	09/628,630	Rabe et al.	7/31/2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on Dec. 8, 2000

Dana M. Kendall 43,709
Name of Attorney Registration No.
[Signature]
Signature of Attorney



Case 7730R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
RABE ET AL. :
Serial No.: 09/629,734 : Group Art Unit: 3751
Filed: July 31, 2000 : Examiner:

For: **ELECTROSTATICALLY-SPRAYABLE TOPICAL COMPOSITIONS
HAVING INSULATING EXTERNAL PHASE AND CONDUCTIVE
INTERNAL PHASE**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
DEC 19 2000
TC 3700 MAIL ROOM

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO-1449 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.


(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed. It is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311 as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR


☐ (3) Copies of all said documents, except document No.'s ____, were submitted and considered in parent application U.S. Patent Application Serial No. ____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s ____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s ____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is on the attached page, except where a full English language translation is provided.


☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page, the copies of which are attached.

☐ Additional information is attached.


Respectfully submitted,

By 
 Dara M. Kendall
 Attorney for Applicants
 Registration No. 43,709
 (513) 627-0081

RECEIVED
 DEC 19 2000
 TC 3700 MAIL ROOM

, 2000
 Miami Valley Laboratories
 P. O. Box 538707
 Cincinnati, OH 45253-8707

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
7729R	09/628,631	Yen et al.	7/31/2000
7731R	09/629,765	Rabe et al.	7/31/2000
7732R	09/628,630	Rabe et al.	7/31/2000



FORM PTO-1449

Sheet 1 of 2

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	PATENT NO. 7730R		SERIAL NO. 09/629,734
	APPLICANT Rabe et al.		
	FILING DATE 7/31/2000		GROUP 3751

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	01	3,012,969	12/12/61	van der Minne et al.	252	153	
	02	4,079,894	03/21/78	Harjar et al.	239	526	
	03	4,122,845	10/31/78	Stouffer et al.	128	66	
	04	4,143,819	03/13/79	Hastings	239	707	
	05	4,194,696	03/25/80	Harjar	239	707	
	06	4,258,073	03/24/81	Payne	427	1	
	07	4,776,515	10/11/88	Michalchik	239	3	
	08	5,200,248	04/06/93	Thompson et al.	428	131	
	09	5,222,663	06/29/93	Noakes et al.	239	3	
	10	5,229,105	07/20/93	Wilmsmann	424	59	
	11	5,268,166	12/07/93	Barnett et al.	424	047	
	12	5,296,681	03/22/94	Tschauder	219	410	
	13	5,322,684	06/21/94	Barnett et al.	424	47	
	14	5,422,630	06/06/95	Quinn et al.	340	661	
	15	5,468,488	11/21/95	Wahi	424	78.03	
	16	5,494,674	02/27/96	Barnett et al.	424	401	
	17	5,505,937	04/09/96	Castrogiovanni et al.	424	64	
	18	5,519,159	05/21/96	Narabe et al.	558	169	
	19	5,662,890	09/02/97	Punto et al.	424	59	
	20	5,674,481	10/07/97	Wahi	424	78.03	
	21	5,800,816	09/01/98	Brieva et al.	424	63	
	22	5,945,111	08/31/99	Esser	424	401	

FOREIGN PATENT DOCUMENTS



		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	23	BE 882,449	07/16/80	Belgium	B05B	--	X
	24	BE 882,450	07/16/80	Belgium	B05B	--	X
	25	EP 0 096,731	12/28/83	EPO	A61N	1/04	X
	26	EP 0 523 960	01/20/93	EPO	B05D	1/ 04	
	27	EP 0 523 961	01/20/93	EPO	B05D	1/ 04	
	28	EP 0 523 962	01/20/93	EPO	B05D	1/ 04	
	29	EP 0 523 963	01/20/93	EPO	B05D	1/ 04	
	30	EP 0 523 964	01/20/93	EPO	B05D	1/ 04	
	31	EP 0 544 158	06/02/93	EPO	C08F	26/06	X
	32	FR 2,127,433	10/13/72	France	C14	11/00	X
	33	GB 2 128 900	05/10/84	Great Britain	B05B	5/06	
	34	GB 2 273 673	06/29/94	Great Britain	B05B	5/025	
	35	GB 2 273 872	07/06/94	Great Britain	B05B	5/025	
	36	JP 7-60166	03/07/95	Japan	B05B	5/025	X
	37	JP 56-097,214	08/05/81	Japan	A61K	7/13	X
	38	JP 10-146216	06/02/98	Japan	A45D	33/38	X
	39	SU 867 927	09/30/81	USSR	C14B	1/54	X
	40	WO 94/11119	05/26/94	PCT	B05D	1/ 04	
	41	WO 94/27560	12/08/94	PCT	A61K	7/02	
	42	WO 95/29758	11/09/95	PCT	B05B	5/025	
	43	WO 96/10459	04/11/96	PCT	B05B	5/057	
	44	WO 96/11062	04/18/96	PCT	B05B	5/053	
	45	WO 97/33527	09/18/97	PCT	A61B	19/00	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE



FORM PTO-1449

Sheet 2 of 2

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY. DOCKET NO. 7730R	SERIAL NO. 09/629,734
	APPLICANT Rabe et al.	
	FILING DATE 7/31/2000	GROUP 3751

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	46	Cook, T.H., et al., "Topographics of Dry Skin, Non-dry Skin, and Cosmetically Treated Dry Skin as Quantified by Skin Profilometry", J. Soc. Cosmet. Chem., Vol. 36, pp. 143-152 (Mar/Apr 1985)
	47	Dorogi, P.L., et al., "Assessment of Skin Conditions Using Profilometry", Cosmetics & Toiletries, Vol. 104, pp. 39-44 (Mar 1989)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE